Evaluating the clinical and financial impact of severe sepsis with Medicare or other administrative hospital data

American Journal of Health-System Pharmacy

Volumn 63, Issue 6, 2006, Pages 575-581

  Ernst, Frank R ^a   Malatestinic, William N ^a   Linde Zwirble, Walter T ^b  

^a ELI LILLY AND COMPANY   (United States)

^b ZD Associates LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

AGING; ARTIFICIAL VENTILATION; CAUSE OF DEATH; CLINICAL PATHWAY; DIAGNOSIS RELATED GROUP; HOSPITAL COST; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; INTERNATIONAL CLASSIFICATION OF DISEASES; LENGTH OF STAY; MEDICAID; MEDICARE; MORTALITY; NOTE; PRIORITY JOURNAL; REIMBURSEMENT; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNITED STATES;

EID: 33645052708     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050214     Document Type: Note

References (31)

1. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101: 1644-55.
2. Sands K, Bates DW, Lanken PN et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 1997; 278: 234-40.
3. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcomes, and associated costs of care. Crit Care Med. 2001; 29:1303-10.
4. Braun LA, Riedel AA, Cooper LM. Severe sepsis in managed care: analysis of incidence, one-year mortality and associated costs of care. JMCP. 2004; 10:521-30.
5. Dellinger RP, Carlet JM, Masur H et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004; 32:858-73.
6. Every NR, Hochman J, Becker R et al. Critical pathways: a review. Circulation. 2000; 101:461-5.
7. Epstein RS, Sherwood LM. From outcomes research to disease management: a guide for the perplexed. Ann Intern Med. 1996; 124:832-7.
8. Qmedit. Drivers for using clinical pathways, www.qmedit.com/overview/ main-set.htm (accessed 2005 Jan 21).
9. OpenClinical. Clinical pathways. www.openclinical.org/clinical pathways.html (accessed 2005 Jan 10).
10. Burns SM, Earves S, Fisher C et al. University of Virginia Long Term Mechanical Ventilation Team. Implementation of an institutional program to improve clinical and financial outcomes of mechanically ventilated patients: one-year outcomes and lessons learned. Crit Care Med. 2003; 31:2752-63.
11. Smith BS, Schroeder WS, Tataronis GR. Hospital reimbursement for adult patients with severe sepsis treated with drotrecogin alfa (activated). Hosp Pharm. 2004; 40:146-53.
12. Centers for Medicare and Medicaid Services. Medicare Provider Analysis and Review file. www.cms.hhs.gov/statistics/medpar (accessed 2005 Jan 21).
13. Centers for Medicare and Medicaid Services, Department of Health and Human Services. Medicare program: changes to the hospital inpatient prospective payment system and fiscal year 2003 rates; final rule. Fed Regist. 2002; 67:50132.
14. Cooper LM, Linde-Zwirble WT. Medicare intensive care unit use: analysis of incidence, cost, and payment. Crit Care Med. 2004; 32:2247-53.
15. Jencks SF, Williams DK, Kay TL. Assessing hospital-associated deaths from discharge data. The role of length of stay and comorbidities. JAMA. 1988; 260:2240-6.
16. Iezzoni LI, Foley SM, Daley J et al. Comorbidities, complications, and coding bias. Does the number of diagnosis codes matter in predicting in-hospital mortality? JAMA. 1992; 267:2197-203.
17. Jollis JG, Ancukiewicz M, DeLong ER et al. Discordance of databases designed for claims payment versus clinical information systems. Ann Intern Med. 1993; 119: 844-50.
18. Jollis JG, Peterson ED, DeLong ER et al. The relation between the volume of coronary angioplasty procedures at hospitals treating Medicare beneficiaries and short-term mortality. N Engl J Med. 1994; 331:1625-9.
19. Andrews LB, Stocking C, Krizek T et al. An alternative strategy for studying adverse events in medical care. Lancet. 1997; 349:309-13.
20. Cullen DJ, Sweitzer BJ, Bates DW et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med. 1997; 25:1289-97.
21. Multz AS, Chalfin DB, Samson IM et al. A "closed" medical intensive care unit (MICU) improves resource utilization when compared with an "open" MICU. Am J Respir Crit Care Med. 1998; 157: 1468-73.
22. Hanson CW, Deutschman CS, Anderson HL et al. Effects of an organized critical care service on outcomes and resource utilization: a cohort study. Crit Care Med. 1999; 27:270-4.
23. Pronovost PJ, Jenckes MW, Dorman T et al. Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery. JAMA. 1999; 281:1310-7.
24. Institute of Medicine. Crossing the quality chasm. Washington, DC: National Academy Press; 2001.
25. Pronovost PJ, Waters H, Dorman T. Impact of critical care physician workforce for intensive care unit staffing. Curr Opin Crit Care. 2001; 7:456-9.
26. Wagner TH, Chen S, Barnett PG. Using average cost methods to estimate encounter-level costs for medical surgical stays in the VA. Med Care Res Rev. 2003; 60(suppl 1):15S-36S.
27. Martin GS, Mannino DM, Eaton S et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348:1546-54.
28. Centers for Medicare and Medicaid Services. Medicare Provider Analysis and Review expanded modified record. www.cms.hhs.gov/data/order/medpar_rl.pdf (accessed 2005 Jan 21).
29. Pronovost PJ, Wu AW, Sexton JB. Acute decompensation after removing a central line: practical approaches to increasing safety in the intensive care unit. Ann Intern Med. 2004; 140:1025-33.
30. Kanji S, Betancourt M, Kruse JA et al. Validating the use of ICD-9-based search strategies to identify patients with severe sepsis who may be candidates for drotrecogin alfa (activated) therapy. Pharmacotherapy. 2002; 22:407. Abstract.
31. Betancourt M, McKinnon PS, Massanari RM et al. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures. Pharmacoeconomics. 2003; 21: 1331-40.